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Green Importantly, nearly all low-grade tumors eventually progress to high-grade malignancies (1) . Owing to their infiltrative growth, gliomas are associated with high morbidity and mortality (2) . Even with the most efficient therapy combinations, median survival of GBM patients (grade IV) is less than 15 months, and most patients die within 2 years with 5-year survival less than 3% (3, 4) . In addition, malignant gliomas almost always recur. The recurrent gliomas are very aggressive with one-year survival rate less than 25%.
Therefore, new therapeutic approaches are urgently needed. One of the main challenges is to identify means by which block invasion and recurrence by destroying the invasive tumor satellites that have left the main tumor mass and that cannot be surgically removed. One attractive approach would be to develop drugs/inhibitors that specifically target these satellite tumor cells and the blood vessels they co-opt for growth.
The distinct molecular signatures in the normal and neoplastic tissues have been efficiently exploited using the in vivo phage display screening to identify tissue-specific markers and to survey disease-specific differences (5) . Using this technology, several peptides that specifically target the blood vessels in various normal tissues and in tumors (6) (7) (8) have been isolated. Tumor lymphatic vessels have also been targeted in this manner (9) (10) (11) . Such peptides have been used for targeted delivery of drugs, oligonucleotides, imaging agents, liposomes, nanoparticles, and viruses (12, 13) .
To identify peptides selectively targeting invasive satellites of malignant gliomas we performed an in vivo phage display screen using a tumor model that reproduces the infiltrating glioblastoma phenotype (14, 15) . Because these tumor cells lack HIF-1, they are incapable of inducing tumor angiogenesis and rely on co-opted normal vessels for growth. We describe a peptide named "CooP" that specifically homes to invasive tumor satellites and the vessels in these tumors and other glioblastomas.
Materials and Methods

Cells
Hif-1α-deficient (HIFko) and VEGF-overexpressing mouse astrocytes were propagated as described (15). U87MG human and BT 4 C rat glioma cells (gift from Seppo Ylä-Herttuala, University of Eastern Finland) were maintained in DMEM, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. MDA-MB-231 cells (gift from Jorma Keskioja, University of Helsinki)
were cultured in the RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml 
Generation of stable cell lines
To establish U87MG cells stably expressing MDGI-GFP fusion protein, MDGI gene was cloned to a lentiviral expression vector (pBOB\cag\GFP) containing green fluorescent protein (GFP) (gift from Seppo Ylä-Herttuala, University of Eastern Finland). Lipofectamine 2000 (Invitrogen) was used to complex the GFP/MDGI-GFP-containing expression vector and lentiviral packaging plasmids pLP1, pLP2 and pLP-VSVG (Invitrogen) according to manufacturer´s instructions. Viruscontaining supernatants of transfected 293FT cells were collected at 72h hours and concentrated at 50 000g with Optima L-80 XP ultracentrifuge (SW28 swinging bucket rotor, Beckmann). U87MG cells were transduced with the concentrated MDGI-GFP or GFP viruses. To increase transgenepositive cells transduced cells were sorted with a BD LSR II fluorescence-activated cell sorter (BD Biosciences).
In vivo phage display
We used an NNK-encoded CX 7 C peptide library (gift from Erkki Ruoslahti, Sanford-Burnham Institute, USA) on the T7Select415-1-phage (Novagen). Phage selections were performed as previously described (16) . For the first ex vivo round tumor-derived cell suspension was incubated overnight at 4°C with 5x10 9 plaque-forming units (PFU) of the library. Bound phage was rescued and amplified in E. coli (BLT5615, Novagen), and used for the second round of ex vivo selection.
Ex vivo enriched phage pool was injected into the tail vein of intracranial HIFko tumor-bearing mice, and allowed to circulate for 15 min. Brain, including tumor, was excised, and the recovered and amplified phage was used for the next rounds of in vivo panning. In each round, nonrecombinant control phage was injected to a separate mouse to assess the background.
Peptide synthesis
CooP (NH 2 -ACGLSGLGVA-CONH 2 ) and its control peptide (NH 2 -ACVAALNADG-CONH 2 ) were Planar SPECT images were combined to the X-ray image using Matlab software (The MathWorks). Three-dimensional SPECT-reconstruction was carried out using the LumGem software (Gamma Medica) with Butterworth six-order low-pass post-filtering with 0.3 cut-off frequency to obtain 3D images with dimensions of 512x512x512 matrix size in 87x87x87 mm 3 FOV. Both CT and SPECT images were interpolated into final 256x256x256 size by using commercial software (Gamma Medica). Images were combined using IDL software (ITT Visual
Information Solutions) and monitored with the Amira software (Mercury).
Analysis of radioactivity in organs
After the last imaging session animals were sacrificed using CO 2 and tissue samples were collected, weighted and radioactivity was measured in an automated gamma counter. Obtained counts were corrected for background radiation and physical decay. Tissue radioactivity was expressed as percentage of the injected dose per gram of tissue (% ID/g ±SD).
Detection of peptides and antibodies in tissues
Intravenously injected fluorescein-labeled peptides (100 nmoles) or antibodies ( 
Cloning of the MDGI from brain tumor cDNA
RNA was isolated from brains of intracranial HIFko tumor-bearing mice using the Rneasy kit (QIAGEN). RNA from two brains (1 μg) was used for cDNA synthesis by the QuantiTech RT Kit (QIAGEN). Full-length MGDI was cloned to the pcDNA3-9E10 plasmid using the following primers: forward: GGAATTCGCGGACGCCTTTGTCGGTACCTGGAAG; reverse:
CCTCGAGTCACGCCTCCTTCTCATAAGTCCGAGTGCTC.
Tumor xenografts and treatment with targeted Cbl
Athymic female Balb/c nu-nu mice (4-6 wks) were used in tumor experiments. Establishment of intracranial tumors has been described (15). Mice were used for experiments 10-21 days after tumor cell inoculation. To establish subcutaneous tumors, 5x10 6 (18) were used for the immunohistological studies. Antigen retrieval was performed by heating the samples in 10 mM sodium citrate buffer (pH 6.0) using a microwave oven (780W 5 min, 380W 10 min). MDGI was detected from the sections using TSA Indirect Kit (PerkinElmer).
To better visualize the localization of MDGI in gliomas, double immunofluorescence staining of human glioma samples using antibodies against MDGI and PECAM-1 (en endothelial marker) was performed. After deparaffinization sections were blocked with blocking solution (5% BSA, 0.1%Triton X-100 in PBS) and incubated with the appropriate primary antibodies +4°C overnight.
After the PBS washes, sections were incubated 1h at room temperature with fluorescently labeled secondary antibodies (Molecular Probes/Invitrogen) and Hoechst (1 μg/ml) in PBS to visualize the nuclei.
Results
Identification of peptides homing to malignant brain tumors
Due to the infiltrative growth glioblastomas contain invasive tumor satellites that cannot be surgically removed and that contribute to recurrence of the tumors. We performed a combined ex vivo/in vivo phage display screen (16) to isolate peptides capable of homing to these invasive satellites that are nurtured by co-opted vasculature. As a model we used the hypoxia inducible factor deficient transformed murine astrocytes (HIFko) that are incapable of angiogenesis and adapt to that inability by co-opting existing normal vessels, which leads to perivascular invasion and growth as invasive tumor satellites (14, 15) . Two rounds of ex vivo selection using the CX 7 C phage-displayed peptide library on cell suspensions from intracranial (i.c.) HIFko tumors yielded a 5-fold enrichment of phage binding to the tumor-derived cells compared to the control (Fig. 1A) .
We subjected this pre-selected phage pool to in vivo selection to screen for peptides capable of homing to the tumors after intravenous injection. We observed an increase in tumor homing over the control phage from 95-fold in the first in vivo round to approximately 200-fold in the third round (Fig. 1A) . After the third in vivo round we sequenced approximately 60 randomly selected individual clones and searched for enriched peptide sequences. Based on the sequence data we chose five clones to validate their ability to bind and home to the HIFko brain tumors. Phage 11, 34, 36, 50 and 59 all showed high, up to 1700-fold, ex vivo binding to tumor cell suspensions over the control phage. However, phage 11, 50 and 59 showed even higher affinity for the normal brain (Fig. 1B) suggesting that these phage/peptides were rather brain than brain tumor specific. The brain tumor to normal brain ratio was about 13 for phage 34 and over 80 for phage 36 demonstrating preference for brain tumor tissue (Fig. 1B) . Peptides encoded by phage 34 (CSESGLGVA) and 36 (CGLSGLGVA) shared 7/9 amino acids. When we tested the in vivo homing of these phage to the i.c. HIFko tumors, phage 36, hereafter referred to as CooP, showed nearly 20-fold homing to the tumor, while only negligible accumulation in other organs, including liver, kidney, lung, and normal brain, was detected (Fig. 1C) . Phage 34 showed only modest tumor homing, about 3-fold over the control phage (data not shown).
To confirm that the homing was mediated by the CooP peptide and to study the tissue localization of the peptide more precisely we conjugated the synthetic peptide to fluorescein (FITC). We injected the FITC-CooP intravenously to mice bearing i.c. HIFko tumors and allowed it to circulate for 60 minutes. The peptide accumulated in the tumor satellites in the brain (Fig. 1D and E) .
Identification of the tumor satellites was confirmed by staining adjacent tissue sections for SV40 large T antigen to visualize the tumor cells (Fig. 1F) . We detected no CooP peptide in the surrounding histologically normal brain (Fig. 1E) or other tissues examined (data not shown). 
cerebrospinal fluid secreting epithelial structure located in brain ventricles. Since a control peptide (E3) (19) , and the previously reported tumor-homing peptides F3 (19) , and LyP-1 (10) used as additional controls, also produced a similar fluorescent pattern at these sites (data not shown), the signals in these organs were most likely produced by non-specific peptide or fluorescein uptake related to excretion of the peptides.
To assess tumor-type specificity of the CooP peptide we tested its homing to other types of brain tumors. Intravenously injected CooP peptide homed to intracranial U87MG human glioma (Fig. 1G) and rat BT 4 C glioma xenografts (Fig. 1H) . No CooP peptide was detected in orthotopic MDA-MB-231 human breast cancer xenografts (Fig. 1I) . Interestingly, CooP peptide did not home to subcutaneous tumors established from the HIFko cells (Fig. 1J) . CooP peptide also did not home to tumors derived from VEGF-expressing HIFko cells (15), which contained a massive network of angiogenic blood vessels (Fig. 1K) .
Mammary-derived growth inhibitor is the binding partner for the CooP peptide
To identify protein(s) to which the CooP peptide binds in the target tissue, we performed a yeasttwo-hybrid screen (17) . The peptide sequence was introduced into the bait plasmid and cotransformed to bacteria with the target plasmids encoding a murine embryonic (E12.5) cDNA
library. An embryonic library was chosen because the CooP peptide did not home to the normal brain, and many embryonic proteins become upregulated in tumor tissue but are absent in normal adult tissues (e.g. c-Myc, the EDB domain of oncofetal fibronectin (20, 21) and the large isoform of tenascin C (22) . The yeast-two-hybrid screen yielded ten in-frame hits, which were used for sequence identification from the BLAST database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). These To act as a receptor molecule for CooP, MDGI should be expressed either by the tumor cells and/or tumor-associated stromal cells. First, we investigated whether MDGI was expressed in those tumors to which the CooP peptide homed. FITC-labeled CooP peptide was injected intravenously into the mice bearing intracranial HIFko or U87MG gliomas. Tumor sections were then studied for the presence of the peptide as well as for MDGI expression. MDGI was detected both in the U87MG and HIFko xenografts ( Fig. 2B and D) . Furthermore, partial co-localization of MGDI and the peptide was observed in the tumor tissue (arrows in Fig. 2A-D Fig. 2E and F) .
Circulating anti-MDGI antibody localizes to tumor-associated blood vessels
To act as a receptor for a systemically administered peptide MDGI should be accessible via the circulation. Therefore, we next injected goat anti-MDGI antibodies intravenously to U87MG tumor mice and investigated whether the antibodies could be detected in the tumor tissue 60 min post- (Fig. 3A) whereas blood vessels in other tissues such as muscle (Fig. 3B), heart (Fig. 3C ), normal brain (Fig. 3D) , kidney, liver, and lung (data not shown) showed no detectable accumulation of the antibody. Control goat IgG did not accumulate in the tumor or any other tissue examined (Fig. 3E-H) . We also stained tissue sections for MDGI to detect expression of this protein in sites not accessible to the circulating antibody. In addition to the tumor (Fig. 3I) muscle (Fig. 3J) and heart (Fig. 3K) were also positive for MDGI expression. No MDGI expression was detected in normal brain with the antibody (Fig. 3L) . Thus, only tumor MDGI was accessible via the blood circulation, and could therefore act as a specific receptor molecule for the intravenously administered homing peptide and anti-MDGI antibody.
Peptide-based SPECT/CT imaging of brain tumors
Next we studied the potential of the CooP peptide in brain tumor imaging using SPECT/CT. We Inlabeled control peptide was detected in tumor tissue two hours post-injection ( Fig. 4C and D) .
Tumor site radioactivity was approximately 20-fold higher at 15 min post-injection and about 12-fold higher at two hours post-injection compared to the contralateral brain hemisphere, indicating marked CooP peptide accumulation in the malignant tissue (Fig. 4E) . Importantly, only the tumors showed increased accumulation of the CooP peptide compared to the control peptide at 2 hrs post-injection (Fig. 4F) . 
CooP-targeted delivery of chemotherapeutics
Since CooP peptide homed to the brain tumor satellites we wanted to study the potential of CooPtargeted therapy to treat invasive brain tumors. As a proof-of-concept we covalently conjugated clorambucil (Cbl) to the CooP peptide. Since CooP was not taken up by the cells, a cell penetrating peptide sequence (CPP) (23) was added between CooP and Cbl to facilitate conjugate internalization (Fig. 5A ). Based on their infiltrative growth pattern, i.c. HIFko tumors were chosen as a model. We treated the i.c. HIFko tumor-bearing mice with intravenous injections of either saline, free Cbl or CooP-CPP-Cbl (5 mg/kg, 4 mice/group) every second day starting on d5 postimplantation and monitored the weight of the animals during the study. At d14 mice in the saline and free Cbl groups had lost over 10% of their starting weight and had to be sacrificed (Fig. 5B ). In the targeted therapy group mice gained weight and did not show any signs of tumor burden indicating that the CooP-targeted drug treatment prolonged the life span of the animals (Fig. 5B) .
Quantification of tumor satellites in the brain showed significantly (p = 0.045) fewer satellites in the targeted drug treated animals than in the control groups (Fig. 5C ) while no difference in the size of the primary tumor was observed (Fig. 5D ).
MDGI expression in human brain tumors
Our results suggest that MDGI acts as an interacting partner for the CooP peptide in the experimental glioma models. Since MDGI expression in human brain tumors has not been reported earlier, we investigated the presence and localization of MDGI in clinical brain tumor samples by immunohistochemistry. First, we analyzed a panel of astrocyte-derived tumor samples from craniotomy patients. Normal human brain (Fig. 6A ) and grade I astrocytomas (Fig. 6B) did not express MDGI at detectable levels. Interestingly, the majority of the grade II (60%) (Fig. 6C ) and grade III astrocytomas (80%) (Fig. 6D) showed moderate levels of MDGI mostly in the vasculature and in perivascular compartment. Of glioblastomas 17/18 (94%) expressed very high levels of MDGI. The expression was concentrated on perinecrotic areas of the tumors (Fig. 6E and F) .
Sixty-seven per cent of ependymomas ( ( Fig. 6H) showed no MDGI expression. We also had access to a small tissue array of human glioblastomas (n=46). In this analysis 70% (32/46) of gliomas stained positive for MDGI. To investigate MDGI localization in gliomas more carefully we stained paraffin-embedded sections with antibodies against MDGI and an endothelial marker, PECAM-1. MDGI was detected in tumor cells ( Figure 6I -K) and in vascular structures, which were positive for PECAM-1 staining in subsequent sections (Figure 6L-P) . Double-labeling with fluorescently-labeled anti-MDGI and PECAM-1 antibodies showed that both proteins were present in the same cells ( Figure 6Q ). Thus, our results demonstrate that MDGI is present in human brain tumors in a grade-dependent manner, its expression positively correlates with the histological grade of the tumor, and it is expressed both in tumor cells and in blood endothelium.
Discussion
Here we describe identification of a novel homing peptide, CooP, which recognizes an epitope in certain brain tumor cells and tumor-associated endothelium. We provide evidence to the effect that mammary-derived growth inhibitor (MDGI), acts as an interacting partner for CooP in brain tumors, and show that the CooP peptide can be used in selective delivery of an imaging agent and chemotherapeutic into glioblastomas. Finally, we show that human glioblastomas, but not the human normal brain, express MDGI, the CooP receptor.
The CooP peptide appears to have a highly selective specificity as a homing peptide. Binding of the CooP phage to cells isolated from glioblastomas, tumor homing of this phage homing in vivo, and the accumulation the CooP peptide in glioblastomas, but not in the normal brain or other normal tissues demonstrate tumor specificity of the peptide. Our results also suggest further layers of specificity. CooP did not recognize the vessels in HIFko tumors that had been engineered to express VEGF, and unlike the original tumors, were able to induce angiogenesis to provide the vasculature to sustain tumor growth. Also, an orthotopically grown breast cancer was negative for CooP homing. These results show that CooP does not recognize an angiogenesis-specific marker, like most of the currently known tumor-homing peptides do (reviewed in (12) . Tumorhoming peptides and vascular tumor markers that are tumor-type specific have been described (10, 24, 25) . Moreover, CooP did not recognize HIFko tumors grown subcutaneously, suggesting a specificity for brain-derived tumor vasculature. Other than their proximity to tumor cells, there are no markers for vessels co-opted by tumors (as opposed to arising as a result of tumor-induced angiogenesis). Hence it is difficult to prove that CooP specifically recognizes co-opted tumor vessels, but the features discussed above, particularly the lack of binding to angiogenic tumor vessels, strongly suggest that this is the case. No peptide with such specificity has been described before.
Several lines of evidence indicate that the MDGI/FABP3 is the receptor that is recognized by CooP and the selective expression of which endows Coop with the specific homing properties. First, a yeast-2-hybrid screen using the peptide sequence as bait yielded three different MDGI cDNAs suggesting that it binds to the CooP peptide. Second, MDGI overexpression increased binding of CooP to cells in vitro, and homing to tumor xenografts in vivo. Third, circulating antibodies against MDGI accumulated in tumor tissue and were non-detectable in other tissues, indicating that MDGI is accessible through the circulation for intravenously injected ligands. It is noteworthy that MDGI is also expressed in heart and skeletal muscle as previously described (26) differentiation. This function may be separate from its ligand binding function since it can be mimicked by its C-terminal peptide, which cannot bind fatty acids (33, 34) . In sporadic breast cancers the genomic region coding for MDGI is often deleted and MDGI appears to be downregulated in breast cancer cell lines via hypermetylation (35, 36) . Moreover, MDGI has been reported to inhibit the growth of MCF-7 breast cancer cells and reduce their tumorigenicity (37) as well as inhibit invasion and adhesion of MDA-MB-231 breast cancer cells (36) .
On the other hand, ectopic MDGI expression was shown to render breast and lung cancer cells resistant to treatment with the anti-EGFR antibody, cetuximab (36) . In small cell lung cancer MDGI expression is significantly higher in the highly aggressive cells than in their less aggressive subtype (38) . In gastric carcinoma MDGI expression is also associated with tumor aggressiveness, progression, and poor patient survival (39) . Our data show association of increased MDGI expression with high grade of brain tumors and suggest MDGI as a novel marker for highly malignant brain tumors.
In contrast to antibodies, which have been traditionally used for the specific delivery of therapeutic agents to several tumor types (40) (41) (42) (43) , homing peptides are faster and less expensive to produce and non-immunogenic (12, 44) . Coupling of therapeutic agents with peptides has also been shown to enhance drug penetration into the target tissue (45) . Due to their small size peptides penetrate better the blood-brain-barrier, enabling the targeted delivery of therapeutic agents directly into the tumor tissue. Therefore, utilization of homing peptides offers an attractive alternative for targeting solid tumors such as malignant gliomas, which adapt to novel anti-angiogenic therapies by increased invasion and co-option of pre-existing vasculature (45) (46) (47) (48) (49) (50) . Importantly, a CooP-peptideconjugated therapeutics reduced the number of tumor satellites in the brain, suggesting that CooPtargeted therapies could be useful as drug carrier to ablate tumor cells in areas that cannot be 
